Wright D, Papadopoulos S, Silva M, Wright A, Nicolaides K H
Institute of Health Research, University of Exeter, Exeter, UK.
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK.
Ultrasound Obstet Gynecol. 2015 Jul;46(1):51-9. doi: 10.1002/uog.14869. Epub 2015 May 27.
To define the contribution of maternal variables which influence the measured level of maternal serum free β-human chorionic gonadotropin (β-hCG) in screening for pregnancy complications.
Maternal characteristics and medical history were recorded and serum free β-hCG was measured in women with a singleton pregnancy attending for three routine hospital visits at 11 + 0 to 13 + 6, 19 + 0 to 24 + 6 and 30 + 0 to 34 + 6 weeks' gestation. For pregnancies delivering phenotypically normal live births or stillbirths ≥ 24 weeks' gestation, variables from maternal demographic characteristics and medical history that are important in the prediction of free β-hCG were determined from a linear mixed-effects multiple regression.
Serum free β-hCG was measured in 94 985 cases in the first trimester, 7879 in the second trimester and 8424 in the third trimester. Significant independent contributions to serum free β-hCG were provided by gestational age, maternal weight, age and racial origin, cigarette smoking, method of conception, diabetes mellitus and family history of pre-eclampsia (PE) in the mother of the patient. The effects of some variables were similar and those for others differed in each trimester. Random-effects multiple regression analysis was used to define the contribution of maternal variables that influence the measured level of serum free β-hCG and express the values as multiples of the median (MoMs). The model was shown to provide an adequate fit of MoM values for all covariates both in pregnancies that developed PE and in those without this pregnancy complication.
A model was fitted to express measured serum free β-hCG across the three trimesters of pregnancy as MoMs after adjusting for variables from maternal characteristics and medical history that affect this measurement.
确定在妊娠并发症筛查中影响母体血清游离β-人绒毛膜促性腺激素(β-hCG)测量水平的母体变量的作用。
记录单胎妊娠女性的母体特征和病史,并在妊娠11+0至13+6周、19+0至24+6周和30+0至34+6周进行三次常规医院就诊时测量其血清游离β-hCG。对于分娩表型正常活产或妊娠≥24周死产的妊娠,通过线性混合效应多元回归确定母体人口统计学特征和病史中对游离β-hCG预测重要的变量。
孕早期测量了94985例血清游离β-hCG,孕中期测量了7879例,孕晚期测量了8424例。孕龄、母体体重、年龄和种族、吸烟、受孕方式、糖尿病以及患者母亲的子痫前期(PE)家族史对血清游离β-hCG有显著的独立影响。某些变量的影响在各孕期相似,而其他变量的影响在各孕期有所不同。采用随机效应多元回归分析来确定影响血清游离β-hCG测量水平的母体变量的作用,并将这些值表示为中位数倍数(MoMs)。结果表明,该模型对发生PE的妊娠和未发生该妊娠并发症的妊娠中的所有协变量的MoM值均拟合良好。
在调整了影响该测量的母体特征和病史变量后,建立了一个模型,将妊娠三个阶段测量的血清游离β-hCG表示为MoMs。